PaxVax announced that it has entered into a definitive agreement to be acquired by Emergent BioSolutions. PaxVax is majority owned by an affiliate of Cerberus Capital and Ignition Growth Capital is a minority shareholder in the company. The agreement will create a significant focus on protecting against emerging and overlooked infectious diseases through the development and commercialization of novel specialty vaccines, while ensuring uninterrupted supply of Vaxchora and Vivotif. PaxVax has integrated capabilities across R&D, manufacturing and commercial operations that add value to Emergent's core business. The combined company will support the development of even more vaccines in areas of significant unmet need, with a commitment to addressing emerging and recalcitrant global health threats. PaxVax marketed assets include Vaxchora, the only FDA approved and Advisory Committee on Immunization Practice, or ACIP, recommended vaccine for protection against cholera, a disease caused by Vibrio cholerae serogroup O1, and Vivotif, an oral vaccine for typhoid fever that is currently licensed for sale in 27 countries. The acquisition is subject to customary closing conditions, including U.S. antitrust regulatory approval, and is expected to close in Q4.
